Abstract: An artificial retina that includes: (i) a substrate; (ii) a first layer, placed onto said substrate and including photovoltaic material portions separated by at least one insulating material portion; and (iii) a second layer, placed onto said first layer and including conductive material portions separated by at least one insulating material portion. In said artificial retina, the photovoltaic material includes a titanium dioxide semiconductor.

Abstract: A device for controlled translational displacement of an elongated element that terminates in a frontal functional end, in particular an instrument/tool that is designed to be brought to an internal site in a patient, more particularly an exploratory instrument/surgical tool placed in a catheter or in an operating channel or working channel of a flexible endoscope, whereby the device includes a linear actuator that acts at the rear end of the elongated element that is located opposite its frontal functional end. The device that is characterized in that the actuator includes of a direct-drive electromagnetic linear motor with a shaft that moves in translation relative to a stator and that drives the elongated element, whereby the shaft can also be coupled to a rotary motor.

Abstract: The invention relates to oligonucleotide-oligocation molecules AiBjH that can be synthetized via automated phosphoramidite chemistry having oligonucleotides moieties Ai and oligocations moieties Bj, wherein •Ai is an i-mer oligonucleotide residue, with i=5 to 50, where nucleotide A is an oligomer with naturally or non naturally occurring nucleobases and/or pentafuranosyl groups and/or native phosphodiester bonds, for example selected from the group comprising deoxyribo, ribo, locked (LNA) nucleotides as well as their chemical modifications or substitutions such as phosphorothioate, 2?-fluoro, 2?-O-alkyl, or a marker group such as a fluorescent agent, •Bj is a j-mer organic oligocation moiety, with j=1 to 50, where B is selected from the group comprising •—HPO3—R1—(X—R2n)n1—X—R3—O—, where R1, R2n and R3, identical or different, are lower alkylene, X is NH or NC(NH2)2, n varies from 1 to 5 and n1=2 to 20, •—HPO3—R4—CH(R5X1)—R6—O—, where R4 is lower alkylene, R5 and R6, identical or different, are lower alkylene

Abstract: The present invention relates to the use of acylthiourea or acylurea derivatives for the treatment of pathologies involving a tissue dysfunction associated with a deregulation of the Hedgehog protein signalling pathway, and also to novel acylthiourea or acylurea derivatives as such, to their use as a medicinal product, and to pharmaceutical compositions containing them.

Abstract: A method for preventing or treating cardiomyopathy due to energy failure in a subject in need thereof is provided. The method comprises administering to the subject a therapeutically effective amount of a vector which comprises a nucleic acid sequence encoding a gene that can reverse energy failure. An exemplary cardiomyopathy is that which is associated with Friedreich ataxia and an exemplary nucleic acid sequence comprises a nucleic acid that encodes frataxin (FXN).

Abstract: The invention relates to novel chemical compounds, compositions and methods of making and using the same. In particular, the invention provides pyridazine compounds and/or related heterocyclic derivatives, compositions comprising the same, and methods of making and using pyridazine compounds and/or related heterocyclic derivatives and compositions comprising the same, for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications.

Abstract: Disclosed are macrocyclic compounds of formulae I, I?, II, II?, III, III?, IV, and V, which are analogs of the pochonin resorcylic acid lactones, pharmaceutical compositions comprising the compounds, and methods and uses comprising the compounds for the treatment of diseases mediated by kinases and Heat Shock Protein 90 HSP90.

Abstract: A method is provided for modifying a surface of a solid conducting material, which includes applying a potential difference between this surface and a surface of another conducting solid material positioned facing it, and wherein, simultaneously, the surface (S) is put into contact with a liquid medium comprising in solution triarylamines (I): while subjecting these triarylamines (I) to electromagnetic radiation, at least partly converting them at into triarylammonium radicals. Also provided is a conducting device which includes two conducting metal materials, the surfaces of which, (S) and (S?) respectively, are electrically interconnected through an organic material comprising conducting fibrillar organic supramolecular species comprising an association of triarylamines of formula (I).

Abstract: The invention relates to novel eucomic acid (2-(4-hydroxybenzyl)malic acid) derivatives or plant extracts comprising such derivatives, and also to cosmetic or dermatological compositions containing these compounds or these extracts, and to cosmetic care methods using said compositions.

Abstract: The invention relates to a method for providing organic, semi-organic, mineral, inorganic and hybrid thin layers and thin layers containing nanoparticles, by simultaneous or alternate spraying of solutions of reactive partners (that is polymer/polymer interacting by hydrogen bonding, polyelectrolyte/small oligo-ion, inorganic compounds, etc.) on the surface of a solid substrate.

Abstract: The invention relates to novel fluorescent compounds derived from non-fluorinated dipyrromethene-boron, to a method for preparing same and to the use thereof for the fluorescent marking of biological molecules. The invention also relates to biological molecules marked with said fluorescent compounds, and to the use thereof in detection methods such as medical diagnosis methods. More particularly, the detection methods of the invention are particularly useful for diagnosing neurodegenerative diseases such as Alzheimer's disease.

Abstract: The invention relates to compounds of formula (I), and the use thereof as a drug, particularly for the treatment of tumors associated with hyperactivation of the hedgehog protein signaling pathway, treatment of neurodegenerative diseases, treatment of diseases related to cerebral development (holoprosencephaly), for stem cell monitoring treatment of cerebrovascular accidents and cardiovascular accidents, treatment of diseases involving oligodendrocytes and diseases involving neurolemmocytes, for application thereof in vitro for modulating human or animal stem cell renewal, and for the treatment of diabetes. The invention also relates to pharmaceutical compositions having a compound of formula (I).

Abstract: A method for manufacturing a spin injector device, comprising the following steps of: a) forming a metal protection layer on a face of a substrate, so as to restrict or prevent oxidation and/or contamination of said face by its environment, the face being magnetic and electrically conductive, the protection layer being of a diamagnetic or paramagnetic nature; b) forming an upper layer onto the protection layer, able to promote a spin bias of electronics sates in the vicinity of the Fermi level of the interface between the protection layer and the upper layer according to an amplitude and a spin referential frame which are defined by the magnetism of the substrate and/or of the face of the substrate, the upper layer being an organic layer of which one or more molecular sites have, in contact with the protection layer, a paramagnetic moment.

Abstract: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, choroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed “Rdcvf1,” that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with nonsufferers, antibodies which recognize this protein, and methods for diagnosing such conditions.

Abstract: The present invention relates to methods and devices for observing eukaryotic cells devoid of cell wall, in particular for observing the cytokinetic ring, the device comprising a plurality of wells suitable for containing only one single eukaryotic cell and characterized in that the dimensions of the wells constrain the cells into an oblong shape with a long axis parallel to the depth of the wells.

Abstract: The present invention relates to a pharmaceutical composition comprising an inhibitor of eIF2?, a compound increasing the expression and/or activity of protein BiP and/or an inhibitor of Caspase-12, preferably an inhibitor of eIF2? and a compound increasing the expression and/or activity of protein BiP. The present invention also relates to pharmaceutical compositions and methods for treating retinal degeneration related to ciliary dysfunction.

Abstract: The present invention relates to a new class of cationic polymers that self-assemble with a pH-sensitive dissolution switch, and their uses to deliver molecules of interest to a cell. The present invention also relates to compositions comprising said cationic polymers non-covalently associated with a molecule of interest, in particular with a siRNA.

Abstract: The invention relates to novel chemical compounds, compositions and methods of making and using the same. In particular, the invention provides pyridazine compounds and/or related heterocyclic derivatives, compositions comprising the same, and methods of making and using pyridazine compounds and/or related heterocyclic derivatives and compositions comprising the same, for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for, research, drug screening, and therapeutic applications.

Abstract: A motorized, modular instrumentation device and an endoscopy system including such device. The motorized, modular instrumentation device includes at least one operational unit mounted on at least one support structure and integrating a motorized medical instrument module including, first, an elongated medical instrument with a tool arranged on one distal end, it being possible to bend the corresponding end portion of the instrument, and second, at least one electrical actuating element controlling the operation of the tool and/or the bending of the distal end portion, via transmission elements extending within the elongated body of the instrument. The actuating element(s) is/are installed in a hollow body connected to the proximal end of the instrument and the hollow body is itself arranged, with rotational guiding, within a reception housing adapted to move, at least translationally, on the support structure, the movements of the hollow body and the reception housing being motorized.

Abstract: The present invention relates to an ex vivo method for preparing induced paraxial mesoderm progenitor (iPAM) cells, said method comprising the step of culturing pluripotent cells in an appropriate culture medium comprising an effective amount of an activator of the Wnt signaling pathway and an effective amount of an inhibitor of the Bone Morphogenetic Protein (BMP) signaling pathway.